Impact of Anti-HER2 Therapies on Overall Survival in Patients with HER2-Positive Metastatic Breast Cancer: Focusing on Intracranial Efficacy of Emerging Treatments.

Cancers (Basel) · 2025 · PMC12606738 · PMID 41228310

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

While the primary endpoint of progression-free survival did not reach statistical significance, the final analysis revealed a significant improvement in overall survival for patients receiving the combination of trastuzumab and pertuzumab compared to trastuzumab alone.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.